Goldman Sachs Sell-side卖方

Caris Life Sciences Inc. (CAI) CMS Releases Preliminary 2027 CLFS Rates; Positive Revision for CAI

Sep 22, 20262 pages页

From the report报告摘录Reimbursement Surge: +44% reimbursement for Caris Assure (blood) to $5,250, driving $15–20M annual revenue upside and eliminating reimbursement risk for blood-based portfolio.

Read the full report + PDF阅读全文与 PDF

The full summary (3 key points) and the original Goldman Sachs PDF are for MastermindX Pro members. 完整摘要（3 个要点）与 Goldman Sachs 原始 PDF 为 MastermindX Pro 会员专享。

Read on MastermindX前往 MastermindX 阅读

Related institutional research相关机构研报

Not investment advice. MastermindX hosts third-party institutional research for reference and education; ratings and views are the authors', not ours. Browse the full Research Vault → 非投资建议。MastermindX 仅收录第三方机构研究，供参考与学习；其中评级与观点均属作者本人。浏览完整研报库 →